Food sensitivities that don't show on allergy tests — the gut-immune story

Medicine isn't wrong to screen for IgE-mediated allergy. IgE-mediated allergy is a well-characterized immune mechanism — it's what causes peanut anaphylaxis, bee sting reactions, and the classic immediate-onset food allergies — and screening for it has genuine diagnostic value. But IgE is one channel through which the immune system can respond to foods. It is not the only channel. The dismissal that follows a negative allergy panel is based on a category error: it treats IgE-negative as equivalent to no immune involvement, which is only true if IgE is the only relevant pathway. It isn't.

The IgG-mediated pathway is the one most commonly discussed in the food sensitivity literature and also the most controversial, which creates a confusing landscape for patients trying to understand their own experience. IgG antibodies against food proteins are measurable and are produced by a significant fraction of people against a wide range of foods. The controversy is about what those IgG antibodies mean — whether elevated IgG against, say, wheat protein represents an active pathological immune response or simply normal exposure-related immune tolerance. The honest answer is that the research hasn't fully resolved this, and IgG food sensitivity testing is inconsistently validated. But the controversy about IgG testing doesn't mean that IgG-mediated or delayed immune reactions to foods don't exist. It means the test currently available to identify them is an imperfect proxy, and the clinical picture is more complex than the test can capture.

Mast cell activation is a more mechanistically robust explanation for a large subset of food sensitivities, and it's one that conventional allergists are increasingly willing to engage with. Mast cells are immune cells densely distributed in the gut mucosa, skin, respiratory tract, and connective tissue. They carry surface receptors for IgE, but they also respond to a wide range of other activation signals — complement proteins, neuropeptides, certain food chemicals, gut dysbiosis-derived metabolites, temperature, and mechanical stimulation. In people with mast cell hyperreactivity or Mast Cell Activation Syndrome, mast cells degranulate in response to stimuli that would not trigger a response in a normal immune system. They release histamine, tryptase, prostaglandins, leukotrienes, and cytokines that produce symptoms in essentially every organ system: gut cramping and bloating, skin flushing and hives, brain fog, joint pain, fatigue, and airway reactivity. These are IgE-independent responses. They will not appear on a standard allergy panel. The foods that trigger them are often histamine-rich foods (fermented foods, aged cheeses, wine, leftovers), histamine-liberating foods, and foods high in other bioactive amines — though trigger lists are individual and often idiosyncratic.

Histamine intolerance is a related but distinct mechanism that often co-occurs with mast cell reactivity. Histamine is both a neurotransmitter and an immune mediator, and it's also present in many foods. The enzyme DAO (diamine oxidase) degrades dietary histamine in the gut; a second enzyme, HNMT (histamine N-methyltransferase), degrades histamine in tissues. When DAO activity is insufficient — due to genetic polymorphisms, gut inflammation, nutrient deficiencies, or gut dysbiosis — dietary histamine is not adequately degraded before it's absorbed, producing systemic histamine load. The symptoms are those of too much histamine in circulation: headaches, flushing, nasal congestion, itching, gut symptoms, and cognitive effects. The foods implicated — wine, hard cheeses, fermented vegetables, smoked fish, certain fruits — are consistently high-histamine or histamine-liberating. Standard allergy panels don't measure DAO activity or histamine load.

Intestinal permeability — often called leaky gut in popular health writing, which has given it a reputation as vague or unvalidated — is a real physiological phenomenon with measurable markers and an understood mechanism. The intestinal epithelium is designed to be selectively permeable: it absorbs nutrients while maintaining a barrier against the passage of bacteria, large protein fragments, and bacterial products like lipopolysaccharide (LPS). Tight junction proteins — occludin, claudin, zonulin — maintain the integrity of that barrier. Chronic gut inflammation, dysbiosis, non-steroidal anti-inflammatory use, alcohol, and certain dietary patterns all impair tight junction function. When the barrier is disrupted, antigen translocation occurs: partially digested food proteins cross the epithelial barrier and encounter the immune cells beneath it in a context that promotes sensitization rather than tolerance. The immune system learns, incorrectly, to mount a response to food proteins that should be recognizable as self.

This mechanism explains one of the most clinically puzzling features of food sensitivities: that they develop in adulthood in people who previously tolerated those foods without issue. The gut barrier disruption can be a relatively recent development — driven by a period of significant antibiotic use, a gut infection, stress, or dietary changes — that creates new immunological relationships with foods that were previously benign. It also explains why people with longstanding gut issues often experience expanding food sensitivity — more foods become problematic over time, not fewer — because ongoing barrier dysfunction continues to present antigens in sensitizing contexts.

The microbiome dimension is tightly connected. Gut bacteria regulate mucosal immunity, maintain the integrity of the epithelial barrier, compete with pathogenic organisms, and produce metabolites — short-chain fatty acids in particular — that support anti-inflammatory immune regulation throughout the body. Dysbiosis, whether driven by antibiotics, diet, or chronic stress, changes the immune regulatory environment of the gut in ways that can increase sensitivity to foods that a healthy microbiome would have trained the immune system to tolerate. Certain bacterial species are specifically associated with regulation of oral tolerance to food antigens. Their absence doesn't create allergy in the IgE sense. It changes the immunological context in which foods are processed.

The diagnostic landscape here is genuinely difficult, and honesty matters: there is no single clean test that maps food sensitivities with the precision that skin prick testing maps IgE-mediated allergy. IgG food panels have variable clinical validity. Mast cell tryptase is usually normal in MCAS during periods between reactions, and provocation testing is the more reliable diagnostic tool. DAO activity testing is available but not widely standardized. Zonulin as a marker of intestinal permeability is measurable but not clinically validated at a level that makes it definitive. In this environment, elimination protocols — carefully structured, properly timed, with systematic reintroduction — remain the most clinically useful diagnostic tool available for food sensitivity characterization. A well-executed elimination diet run over six to eight weeks, followed by individual reintroduction with symptom tracking, generates clinical information that no panel currently available can match. It's labor-intensive and imprecise at the margins, but it works.

The peptide research intersection is worth acknowledging briefly. BPC-157 has been studied for its potential to support gut mucosal healing and barrier integrity in the context of gut permeability, with proposed mechanisms involving the upregulation of tight junction protein expression and promotion of angiogenesis in healing tissue. KPV, a tripeptide derived from alpha-MSH, has been researched for its anti-inflammatory properties in gut tissue contexts, including potential modulation of cytokine responses in the intestinal mucosa. Neither is an approved therapeutic; both represent an area of active research with a mechanistic basis that is coherent with the biology of gut barrier dysfunction. They're most relevant as potential adjuncts in a broader gut repair protocol under clinician supervision, not as standalone interventions.

The foundational work — if gut-immune food reactivity is the mechanism — involves addressing what created the dysregulation in the first place. That usually means removing the obvious triggers first, then working on the gut environment that made the sensitivities possible: reducing the inflammatory dietary load that sustains gut permeability, supporting microbiome diversity through fiber diversity and fermented foods, addressing the dysbiosis if it's measurable, and managing the stress physiology that drives gut permeability through the cortisol-tight junction connection.

When symptoms persist after reasonable dietary and gut-healing intervention — when the reintroduction testing shows that dozens of foods are problematic, when the pattern suggests mast cell involvement, when there are symptoms outside the gut in multiple organ systems — that's the signal that a specialist evaluation is warranted. Allergist-immunologists with MCAS experience, gastroenterologists with interest in motility and gut permeability, and functional medicine practitioners who work systematically with the gut-immune axis all have something to offer that's beyond the general practitioner's default framework.

What the negative allergy panel is actually telling you is that IgE isn't the mechanism. It is not telling you that your experience isn't real. The immune system has many ways of reacting to food. Most of them don't show up on the test you were given.